US drugmaker EQRx (Nasdaq: EQRX), founded on the principle of developing and delivering innovative medicines to patients at radically lower prices, saw its share price leap more than 19% to $2.04 by mid-morning (having hit a high of $2.22), on news of a takeover bid.
Clinical-stage oncology drug developer Revolution Medicines (Nasdaq: RVMD) came to EQRx’ rescue with a plan to acquire the company in an all-stock transaction.
The transaction is intended to add more than $1 billion in net cash to Revolution Medicines’ balance sheet and reinforce and sustain the latter’s parallel development approach for its extensive RAS(ON) Inhibitor pipeline in multiple RAS-driven cancers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze